Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Atea Pharmaceuticals Inc stock

Learn how to easily invest in Atea Pharmaceuticals Inc stock.

Atea Pharmaceuticals Inc is a biotechnology business based in the US. Atea Pharmaceuticals Inc shares (AVIR) are listed on the NASDAQ and all prices are listed in US Dollars. Atea Pharmaceuticals Inc employs 63 staff and has a trailing 12-month revenue of around $225 million.

How to buy shares in Atea Pharmaceuticals Inc

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AVIR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Atea Pharmaceuticals Inc stock price (NASDAQ: AVIR)

Use our graph to track the performance of AVIR stocks over time.

Atea Pharmaceuticals Inc shares at a glance

Information last updated 2022-09-26.
Latest market close$5.60
52-week range$5.31 - $46.91
50-day moving average $7.83
200-day moving average $7.26
Wall St. target price$9.00
PE ratio 45.8333
Dividend yield $0 (0%)
Earnings per share (TTM) $0.12

Buy Atea Pharmaceuticals Inc shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Atea Pharmaceuticals Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atea Pharmaceuticals Inc price performance over time

Historical closes compared with the close of $5.6 from 2022-09-29

1 week (2022-09-23) -3.45%
1 month (2022-08-30) -26.32%
3 months (2022-06-30) -21.13%
6 months (2022-03-30) -20.90%
1 year (2021-09-30) -84.03%
2 years (2020-09-26) N/A
3 years (2019-09-26) N/A
5 years (2017-09-26) N/A

Is Atea Pharmaceuticals Inc stock undervalued or overvalued?

Valuing Atea Pharmaceuticals Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atea Pharmaceuticals Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Atea Pharmaceuticals Inc's P/E ratio

Atea Pharmaceuticals Inc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, Atea Pharmaceuticals Inc shares trade at around 46x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Atea Pharmaceuticals Inc's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Atea Pharmaceuticals Inc's EBITDA

Atea Pharmaceuticals Inc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $24.6 million.

The EBITDA is a measure of a Atea Pharmaceuticals Inc's overall financial performance and is widely used to measure a its profitability.

To put Atea Pharmaceuticals Inc's EBITDA into context you can compare it against that of similar companies.

Atea Pharmaceuticals Inc financials

Revenue TTM $225 million
Operating margin TTM 10.92%
Gross profit TTM $184.2 million
Return on assets TTM 1.96%
Return on equity TTM 2.47%
Profit margin 6.9%
Book value $7.93
Market capitalisation $457.9 million

TTM: trailing 12 months

Atea Pharmaceuticals Inc share dividends

We're not expecting Atea Pharmaceuticals Inc to pay a dividend over the next 12 months.

You may also wish to consider:

Atea Pharmaceuticals Inc overview

Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Atea Pharmaceuticals Inc is owned by insiders or institutions?
Currently 10.522% of Atea Pharmaceuticals Inc shares are held by insiders and 70.082% by institutions.
How many people work for Atea Pharmaceuticals Inc?
Latest data suggests 63 work at Atea Pharmaceuticals Inc.
When does the fiscal year end for Atea Pharmaceuticals Inc?
Atea Pharmaceuticals Inc's fiscal year ends in December.
Where is Atea Pharmaceuticals Inc based?
Atea Pharmaceuticals Inc's address is: 125 Summer Street, Boston, MA, United States, 02110
What is Atea Pharmaceuticals Inc's ISIN number?
Atea Pharmaceuticals Inc's international securities identification number is: US04683R1068

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site